MARKET

CLBS

CLBS

Caladrius
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.610
-0.100
-5.85%
After Hours: 1.630 +0.02 +1.24% 16:52 10/26 EDT
OPEN
1.700
PREV CLOSE
1.710
HIGH
1.711
LOW
1.580
VOLUME
125.73K
TURNOVER
--
52 WEEK HIGH
3.640
52 WEEK LOW
1.050
MARKET CAP
31.11M
P/E (TTM)
-1.9682
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°
BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360°, being held virtually on October 26-27, 2020. Breakout Session Details: Title: Tracking Personalized Medications in Gene and Cell Therapy Date/Time: October 26, 2020 at 3:00 p.m.For more information on the 8th annual CMO Summit 360°, or to register, please click here.About Caladrius BiosciencesCaladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first- in-class cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage in patients with COVID-19 who are experiencing respiratory failure, for which the Company recently initiated a clinical trial as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2a clinical trial in the U.S. and slated to begin a comprehensive Phase 2b trial in the U.S. during 4Q20 for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the company, please visit www.caladrius.com.Contact:Investors: Caladrius Biosciences, Inc. John Menditto Vice President, Investor Relations and Corporate Communications Phone: +1-908-842-0084 Email: jmenditto@caladrius.com Media: W2O Group Christiana Pascale Phone: +1-212-257-6722 Email: cpascale@w2ogroup.com
GlobeNewswire · 5d ago
Caladrius Biosciences (NASDAQ:CLBS) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 10/17 14:14
Caladrius Biosciences (CLBS) Investor Presentation - Slideshow
The following slide deck was published by Caladrius Biosciences, Inc. in conjunction with this event.
Seekingalpha · 10/14 17:29
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage
Patient screening begins immediately at NYU Langone Health The study will explore the ability of CLBS119 to restore normal oxygen levels in patients who have recovered from the virus but require continued supplemental oxygen due to COVID-19-induced vascular damageBASKING RIDGE, N.J., Oct. 08, 2020 (
GlobeNewswire · 10/08 13:00
Caladrius Bio launches CLBS119 study to repair COVID-19-induced lung damage
Caladrius Biosciences (CLBS) has opened its proof-of-concept study of CLBS119 (peripheral blood-derived autologous CD34+ cells) as a treatment and repair of COVID-19-induced lung damage and begun screening prospective patients for inclusion
Seekingalpha · 10/08 12:34
Caladrius Biosciences Opens Study Of CLBS119 To Repair Coronavirus-Induced Lung Damage
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage Patient screening begins immediately at NYU Langone Health   The study will explore the ability of
Benzinga · 10/08 12:07
Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa
BASKING RIDGE, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical
GlobeNewswire · 10/07 20:05
Caladrius Biosciences to Present at the BIO Investor Forum Digital
BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive
GlobeNewswire · 10/06 21:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLBS. Analyze the recent business situations of Caladrius through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLBS stock price target is 10.50 with a high estimate of 18.50 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 1.45M
% Owned: 7.52%
Shares Outstanding: 19.32M
TypeInstitutionsShares
Increased
3
443.69K
New
6
87.69K
Decreased
5
6.99K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Independent Director
Gregory Brown
President/Chief Executive Officer/Director
David Mazzo
Executive Vice President
Douglas Losordo
Senior Vice President/General Counsel/Secretary
Todd Girolamo
Director
Michael Davidson
Independent Director
Steven Klosk
Independent Director
Steven Myers
Independent Director
Cynthia Schwalm
Independent Director
Peter Traber
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLBS
Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. It also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Caladrius Biosciences Inc stock information, including NASDAQ:CLBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLBS stock methods without spending real money on the virtual paper trading platform.